Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial

被引:16
|
作者
Armani, Rachel G. [1 ]
Carvalho, Aluizio B. [1 ]
Ramos, Christiane, I [1 ]
Hong, Valeria [2 ]
Bortolotto, Luiz A. [2 ]
Cassiolato, Jose Luiz [3 ]
Oliveira, Natacha F. [4 ]
Cieslarova, Zuzana [5 ]
do Lago, Claudimir L. [5 ]
Klassen, Aline [4 ]
Cuppari, Lilian [1 ]
Raj, Dominic S. [6 ]
Canziani, Maria Eugenia F. [1 ]
机构
[1] Univ Fed Sao Paulo, Div Nephrol, Dept Med, Sao Paulo, Brazil
[2] Univ Sao Paulo, Heart Inst, Sao Paulo, Brazil
[3] CARDIOS, Adv Cardiol Equipment, Sao Paulo, Brazil
[4] Univ Fed Sao Paulo, Dept Chem, Diadema, Brazil
[5] Univ Sao Paulo, Inst Chem, Sao Paulo, Brazil
[6] George Washington Univ, Div Kidney Dis & Hypertens, Washington, DC USA
基金
巴西圣保罗研究基金会;
关键词
chronic kidney disease; endothelial dysfunction; flow-mediated dilatation; fructooligosaccharide; gut microbiota; CHRONIC KIDNEY-DISEASE; BOUND UREMIC TOXINS; OXIDATIVE STRESS; INDOXYL SULFATE; BRACHIAL-ARTERY; GUT MICROBIOME; PREBIOTICS; ATHEROSCLEROSIS; INTERLEUKIN-6; VASODILATION;
D O I
10.1093/ndt/gfaa335
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Microbiota-derived uremic toxins have been associated with inflammation that could corroborate with endothelial dysfunction (ED) and increase cardiovascular risk in patients with chronic kidney disease (CKD). This trial aimed to evaluate the effect of the prebiotic fructooligosaccharide (FOS) on endothelial function and arterial stiffness in nondialysis CKD patients. Methods. In a double-blind controlled trial, 46 nondiabetic CKD patients were randomized to receive 12 g/day of FOS or placebo (maltodextrin) for 3 months. Total p-cresyl sulfate (PCS) and indoxyl sulfate by high-performance liquid chromatography, urinary trimethylamine N-oxide by mass spectrometry, C-reactive protein, interleukin-6 (IL-6), serum nitric oxide and stroma-derived factor-1 alfa were measured at baseline and at the end of follow-up; endothelial function was assessed through flow-mediated dilatation (FMD) and arterial stiffness by pulse wave velocity (PWV). Results. The mean (+/- standard deviation) age of the study participants was 57.6 +/- 14.4 years, with an estimated glomerular filtration rate of 21.3 +/- 7.3 mL/min/1.73 m(2). During the follow-up, regarding the inflammatory markers and uremic toxins, there was a significant decrease in IL-6 levels (3.4 +/- 2.1 pg/mL versus 2.6 +/- 1.4 pg/mL; P = 0.04) and a trend toward PCS reduction (55.4 +/- 38.1 mg/L versus 43.1 +/- 32.4 mg/L, P = 0.07) only in the prebiotic group. Comparing both groups, there was no difference in FMD and PWV. In an exploratory analysis, including a less severe ED group of patients (FMD >= 2.2% at baseline), FMD remained stable in the prebiotic group, while it decreased in the placebo group (group effect P = 0.135; time effect P = 0.012; interaction P = 0.002). Conclusions. The prebiotic FOS lowered circulating levels of IL-6 in CKD patients and preserved endothelial function only in those with less damaged endothelium. No effect of FOS in arterial stiffness was observed.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 50 条
  • [21] Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes
    Yiu, Yuen-Fung
    Yiu, Kai-Hang
    Siu, Chung-Wah
    Chan, Yap-Hang
    Li, Sheung-Wai
    Wong, Lai-Yung
    Lee, Stephen W. L.
    Tam, Sidney
    Wong, Eric W. K.
    Lau, Chu-Pak
    Cheung, Bernard M. Y.
    Tse, Hung-Fat
    ATHEROSCLEROSIS, 2013, 227 (01) : 140 - 146
  • [22] LVRS improves endothelial function and blood pressure in patients with COPD: A randomized-controlled trial
    Clarenbach, Christian
    Sievi, Noriane
    Brock, Matthias
    Schneiter, Didier
    Weder, Walter
    Kohler, Malcolm
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [23] Polyphenols Have No Impact on Endothelial Function in Patients with Obstructive Sleep Apnea: A Randomized Controlled Trial
    Trzepizur, Wojciech
    Bironneau, Vanessa
    Recoquillon, Sylvain
    Priou, Pascaline
    Meslier, Nicole
    Hamel, Jean-Francois
    Henni, Samir
    Darsonval, Astrid
    Messaoudi, Khaled
    Martinez, Maria Carmen
    Andriantsitohaina, Ramaroson
    Gagnadoux, Frederic
    JOURNAL OF NUTRITION, 2018, 148 (04): : 581 - 586
  • [24] Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD
    Levin, Adeera
    Tang, Mila
    Perry, Taylor
    Zalunardo, Nadia
    Beaulieu, Monica
    Dubland, Joshua A.
    Zerr, Kelly
    Djurdjev, Ognjenka
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (09): : 1447 - 1460
  • [25] Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled Trial
    Akizawa, Tadao
    Asano, Yasushi
    Morita, Satoshi
    Wakita, Takafumi
    Onishi, Yoshihiro
    Fukuhara, Shunichi
    Gejyo, Fumitake
    Matsuo, Seiichi
    Yorioka, Noriaki
    Kurokawa, Kiyoshi
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (03) : 459 - 467
  • [26] Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
    Hayashi, Terumasa
    Maruyama, Shoichi
    Nangaku, Masaomi
    Narita, Ichiei
    Hirakata, Hideki
    Tanabe, Kenichiro
    Morita, Satoshi
    Tsubakihara, Yoshiharu
    Imai, Enyu
    Akizawa, Tadao
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (05): : 608 - 615
  • [27] Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
    Mai Seki
    Toshiaki Nakano
    Shigeru Tanaka
    Yuta Matsukuma
    Kouta Funakoshi
    Toshiaki Ohkuma
    Takanari Kitazono
    Clinical and Experimental Nephrology, 2023, 27 : 358 - 364
  • [28] The effect of a ketogenic diet on weight loss in CKD: a randomized controlled trial in obese stage G1-3a CKD patients
    Zoccali, Carmine
    Bellizzi, Vincenzo
    Minutolo, Roberto
    Mallamaci, Francesca
    Conte, Giuseppe
    De Nicola, Luca
    CLINICAL KIDNEY JOURNAL, 2023, 16 (12) : 2309 - 2313
  • [29] Effects of Uric Acid on Lipid Levels in CKD Patients in a Randomized Controlled Trial
    Bowden, Rodney G.
    Shelmadine, Brian D.
    Moreillon, Jennifer J.
    Deike, Erika
    Griggs, Jackson O.
    Wilsond, Ronald L.
    CARDIOLOGY RESEARCH, 2013, 4 (02) : 56 - 63
  • [30] Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
    Seki, Mai
    Nakano, Toshiaki
    Tanaka, Shigeru
    Matsukuma, Yuta
    Funakoshi, Kouta
    Ohkuma, Toshiaki
    Kitazono, Takanari
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2023, 27 (04) : 358 - 364